We’re thrilled to share that NanoVation Therapeutics has been awarded the prestigious Deal of the Year award at the 27th Annual Life Sciences BC Awards!
This recognition celebrates our partnership with Novo Nordisk, announced in September 2024 — a transformative collaboration that brings together our cutting-edge long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery beyond the liver and Novo Nordisk’s deep expertise in cardiometabolic and rare disease research and development.
Our partnership is designed to accelerate the development of innovative genetic medicines, pushing the boundaries of what’s possible in addressing some of the most challenging diseases. As part of this multi-year agreement, NanoVation receives research funding, up to approximately US$600 million in up-front and milestone payments, and future royalties — a testament to the global impact and potential of our technology.
Being recognized by Life Sciences BC, an organization dedicated to advancing BC’s vibrant life sciences ecosystem, is an incredible honour. This award highlights the strength and creativity of our team and the value of collaboration in driving breakthrough science forward.
The 27th Annual Life Sciences BC Awards Gala will take place on October 2, 2025, at the Vancouver Convention Centre West, where all award winners will be celebrated.
Thank you to our partners, supporters, and the entire NanoVation community for helping us turn bold ideas into reality. We’re just getting started!